Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-molecular-weight heparins: are they all the same?

× No keyword cloud information.

17 in total

Review 1. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors: Andrea Lee; Mark Crowther
Journal: J Thromb Thrombolysis Date: 2011-04 Impact factor: 2.300

Review 2. Low molecular weight heparin and atherosclerosis.

Authors: Dan Hunt
Journal: Curr Atheroscler Rep Date: 2004-03 Impact factor: 5.113

3. Low-molecular-weight heparin prophylaxis of deep vein thrombosis for older patients with restricted mobility: propensity analyses of data from two multicentre, cross-sectional studies.

Authors: José Labarère; Marie-Antoinette Sevestre; Joël Belmin; Annie Legagneux; Marie-Thérèse Barrellier; Hélène Thiel; Philippe Le Roux; Gilles Pernod; Jean-Luc Bosson
Journal: Drugs Aging Date: 2009 Impact factor: 3.923

4. How to handle low-molecular-weight heparins in patients with decreased renal function: an open issue.

Authors: Giuseppe Stefano Netti; Maurizio Margaglione; Loreto Gesualdo
Journal: Intern Emerg Med Date: 2008-09-20 Impact factor: 3.397

Review 5. Venous thromboembolism prophylaxis.

Authors: Jonathan Laryea; Bradley Champagne
Journal: Clin Colon Rectal Surg Date: 2013-09

Review 6. A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation.

Authors: Arun Krishnamoorthy; Thomas Ortel
Journal: Curr Cardiol Rep Date: 2016-10 Impact factor: 2.931

7. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

Authors: Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry
Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981

Review 8. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors: Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal: Drugs Date: 2004 Impact factor: 9.546

9. Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen.

Authors: M S Cunningham; R Gilmore; D O'Donnell; J S O'Donnell
Journal: Ir J Med Sci Date: 2008-08-27 Impact factor: 1.568

10. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.

Authors: A Berges; S Laporte; M Epinat; P Zufferey; E Alamartine; B Tranchand; H Decousus; P Mismetti
Journal: Br J Clin Pharmacol Date: 2007-05-17 Impact factor: 4.335